GlobeNewswire Inc | Feb 1, 2021 07:05AM EST

February 01, 2021

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

-- 14th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD), February 3 5, 2021

uniQure will deliver multiple presentations on the companys gene therapy candidate etranacogene dezaparvovec in patients with hemophilia B. These presentations will include encore clinical data first presented at medical conferences late last year, as well as health economic data.

Further details on the companys presentations will follow closer to the conference dates.

-- Gene Therapy Medical Affairs, February 9 -11, 2021

Eileen Sawyer, Ph.D., vice president, global medical affairs of uniQure, will present Medical Affairs as Partner to Empower Patients Throughout the Drug Development Process on Wednesday, February 10 at 12:20 p.m. ET.

Nick Li., Ph.D., senior director, healthcare economics and outcomes research (HEOR) of uniQure, will present Explore Delivering Therapy Gene Therapy to Patients on Thursday, February 11 at 11:50 a.m. ET.

-- 10th Annual SVB Leerink Global Healthcare Conference, February 22 26, 2021

A fireside chat with Matt Kapusta, chief executive officer, will take place on February 26, 2021 from 3:00 to 3:30 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.

Members of uniQures management team including Matt Kapusta, Ricardo Dolmetsch, Ph.D., president of research & development, and Maria Cantor, chief communications officer, with Chiara Russo, associate director of investor relations and communications, will participate in virtual one-on-one investor meetings throughout the day.

-- 65th Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH), February 22 26, 2021

Professor Wolfgang Miesbach, M.D., Ph.D., of the University Hospital Frankfurt in Germany, will present two-year follow-up data on etranacogene dezaparvovec in hemophilia B, as well as five-year follow-up data on AMT-060, also in patients with hemophilia B.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

uniQure Contacts: FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com